Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 127

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 127
---
 to these emerging therapies.

While our Nano-Mupirocin product candidate
is being evaluated as a potential approach to addressing the critical issue of antibiotic resistance, it faces competition from a range
of traditional and non-traditional antibacterial therapies under development.

Our strategic positioning and ongoing innovation will be key to differentiating
Nano-Mupirocin in this diverse and evolving competitive landscape.

Competition related to ARB (AT1 receptor blocker) novel cancer therapy combination therapy

We also face competition from a wide range of
pharmaceutical and biotechnology companies in the field of cancer therapy, particularly in the development of treatments targeting the
tumor microenvironment (TME) to enhance the efficacy of chemotherapy and immunotherapy. Many of these competitors are working on advanced
therapeutic strategies that include, but are not limited to, targeted therapies, immune checkpoint inhibitors, cancer vaccines, oncolytic
viruses, and cell therapies. These therapies aim to improve drug delivery, overcome TME-induced drug resistance, and modulate the immune
system’s response to cancer.

<div align='center'>81</div>

Several companies are developing liposomal formulations
and other nanoparticle-based delivery systems designed to improve the delivery and efficacy of cancer drugs, including Merrimack Pharmaceuticals
and Celator Pharmaceuticals, that have developed liposomal platforms for chemotherapeutic agents. These platforms aim to enhance drug
accumulation in tumor tissues while minimizing systemic toxicity, similar to our ARB’s intended mechanism of action.

Additionally, AstraZeneca, Roche, and Merck are
advancing the development of therapies targeting the TME, particularly focusing on modulating the immune microenvironment and overcoming
the immunosuppressive barriers within solid tumors. These efforts include the development of novel immune checkpoint inhibitors and agents
targeting CAFs, ECM remodeling enzymes, and other components critical to TME dynamics.

Emerging biotech firms are also exploring innovative
approaches to TME normalization, such as the use of small molecule inhibitors, monoclonal antibodies targeting CAFs or ECM components,
and gene therapy approaches to modulate the TME. These therapies aim to improve the penetration and effectiveness of existing cancer treatments
and may provide direct competition to our ARB technology.

On the technological front, advancements in nanotechnology,
drug formulation, and targeted delivery mechanisms, including the use of targeting ligands and stimuli-responsive release systems, present
potential competition. These technologies aim to enhance the selective accumulation and controlled release of therapeutics within the
TME, which